O	0	6	Single
O	6	7	-
O	7	13	center
O	14	18	long
O	18	19	-
O	19	23	term
O	24	31	results
O	32	36	from
O	37	40	the
O	41	51	randomized
O	52	57	phase
O	57	58	-
O	58	59	3
O	60	66	TARGIT
O	66	67	-
O	67	68	A
O	69	74	trial
O	75	84	comparing
B-intervention	85	99	intraoperative
O	100	103	and
B-control	104	109	whole
I-control	109	110	-
I-control	110	116	breast
I-control	117	126	radiation
I-control	127	134	therapy
O	135	138	for
O	139	144	early
O	145	151	breast
O	152	158	cancer
O	158	159	.

O	160	167	Partial
O	168	174	breast
O	175	186	irradiation
O	187	192	using
O	193	207	intraoperative
O	208	220	radiotherapy
O	221	222	(
O	222	226	IORT
O	226	227	)
O	228	233	after
O	234	240	breast
O	240	241	-
O	241	251	conserving
O	252	259	surgery
O	260	265	could
O	266	268	be
O	269	279	sufficient
O	280	283	for
O	284	285	a
O	286	294	selected
O	295	300	group
O	301	303	of
O	304	310	breast
O	311	317	cancer
O	318	326	patients
O	326	327	.

O	328	330	We
O	331	337	report
O	338	341	the
O	342	349	results
O	350	352	of
O	353	354	a
O	355	361	cohort
O	362	364	of
O	365	373	patients
O	374	378	from
O	379	380	a
O	381	387	single
O	388	394	center
O	395	402	treated
O	403	405	as
O	406	410	part
O	411	413	of
O	414	417	the
O	418	428	randomized
O	429	434	phase
O	434	435	-
O	435	436	3
O	437	443	TARGIT
O	443	444	-
O	444	445	A
O	446	451	trial
O	451	452	.

O	453	461	Patients
O	462	463	(
B-age	463	464	≥
I-age	464	466	50
I-age	467	472	years
O	472	473	)
B-eligibility	474	478	with
I-eligibility	479	482	cT1
I-eligibility	483	486	cN0
I-eligibility	487	490	cM0
I-eligibility	491	494	and
I-eligibility	495	503	invasive
I-eligibility	504	510	ductal
I-eligibility	511	520	histology
I-eligibility	521	523	on
I-eligibility	524	530	biopsy
O	531	535	were
O	536	546	randomized
O	547	554	between
O	555	559	IORT
O	560	564	with
O	565	567	20
O	568	570	Gy
O	571	572	(
O	572	575	arm
O	575	576	-
O	576	577	A
O	577	578	)
O	579	581	or
O	582	595	postoperative
O	596	601	whole
O	601	602	-
O	602	608	breast
O	609	611	RT
O	612	613	(
O	613	617	WBRT
O	617	618	)
O	619	621	up
O	622	624	to
O	625	627	56
O	628	630	Gy
O	631	633	in
O	634	635	2
O	636	638	Gy
O	639	648	fractions
O	649	650	(
O	650	653	arm
O	653	654	-
O	654	655	B
O	655	656	)
O	656	657	.

O	658	673	Postoperatively
O	673	674	,
O	675	683	patients
O	684	686	in
O	687	690	arm
O	690	691	-
O	691	692	A
O	693	697	with
O	698	711	multifocality
O	711	712	,
O	713	727	lymphovascular
O	728	736	invasion
O	736	737	,
O	738	743	nodal
O	744	752	invasion
O	752	753	,
O	754	763	extensive
O	764	775	intraductal
O	776	785	component
O	785	786	,
O	787	795	invasive
O	796	803	lobular
O	804	813	carcinoma
O	813	814	,
O	815	817	or
O	818	827	resection
O	828	835	margins
O	836	837	<
O	837	838	1
O	839	841	cm
O	842	850	received
O	851	861	additional
O	862	875	postoperative
O	876	880	WBRT
O	880	881	.

O	882	889	Between
O	890	894	2002
O	895	898	and
O	899	903	2012
O	903	904	,
B-total-participants	905	908	184
O	909	917	patients
O	918	922	were
O	923	933	randomized
O	933	934	,
O	935	937	of
O	938	942	whom
B-intervention-participants	943	945	90
O	946	948	in
O	949	952	arm
O	952	953	-
O	953	954	A
O	955	958	and
B-control-participants	959	961	90
O	962	964	in
O	965	968	arm
O	968	969	-
O	969	970	B
O	971	975	were
O	976	985	evaluated
O	985	986	.

O	987	993	Median
O	994	1000	follow
O	1000	1001	-
O	1001	1003	up
O	1004	1007	was
O	1008	1009	8
O	1009	1010	.
O	1010	1011	5
O	1012	1017	years
O	1017	1018	.

O	1019	1022	The
B-outcome	1023	1024	5
I-outcome	1024	1025	‑
I-outcome	1025	1029	year
I-outcome	1030	1037	overall
I-outcome	1038	1046	survival
O	1047	1050	was
B-iv-bin-percent	1051	1053	94
I-iv-bin-percent	1053	1054	.
I-iv-bin-percent	1054	1055	4
I-iv-bin-percent	1055	1056	%
O	1057	1059	in
O	1060	1063	arm
O	1063	1064	-
O	1064	1065	A
O	1066	1069	and
B-cv-bin-percent	1070	1072	93
I-cv-bin-percent	1072	1073	.
I-cv-bin-percent	1073	1074	3
I-cv-bin-percent	1074	1075	%
O	1076	1078	in
O	1079	1082	arm
O	1082	1083	-
O	1083	1084	B
O	1085	1086	(
O	1086	1087	p
O	1088	1089	=
O	1090	1091	0
O	1091	1092	.
O	1092	1094	73
O	1094	1095	)
O	1095	1096	.

O	1097	1100	Two
B-outcome	1101	1106	local
I-outcome	1107	1118	recurrences
O	1119	1123	were
O	1124	1132	observed
O	1132	1133	:
B-iv-bin-abs	1134	1137	one
O	1138	1140	at
O	1141	1143	70
O	1143	1144	.
O	1144	1145	3
O	1146	1152	months
O	1153	1155	in
O	1156	1158	an
O	1159	1162	arm
O	1162	1163	-
O	1163	1164	A
O	1165	1172	patient
O	1173	1176	who
O	1177	1185	received
O	1186	1190	IORT
O	1191	1192	+
O	1193	1197	WBRT
O	1198	1201	and
O	1202	1209	another
O	1210	1212	at
O	1213	1214	4
O	1214	1215	.
O	1215	1216	5
O	1217	1223	months
O	1224	1226	in
O	1227	1229	an
O	1230	1233	arm
O	1233	1234	-
O	1234	1235	B
O	1236	1243	patient
O	1244	1247	who
O	1248	1255	refused
O	1256	1259	all
O	1260	1265	forms
O	1266	1268	of
O	1269	1277	adjuvant
O	1278	1287	treatment
O	1287	1288	,
O	1289	1293	thus
O	1294	1303	resulting
O	1304	1306	in
O	1307	1308	a
B-outcome	1309	1310	5
I-outcome	1310	1311	-
I-outcome	1311	1315	year
I-outcome	1316	1321	local
I-outcome	1322	1332	recurrence
O	1333	1335	of
B-iv-bin-percent	1336	1337	0
I-iv-bin-percent	1337	1338	%
O	1339	1341	in
O	1342	1345	arm
O	1345	1346	-
O	1346	1347	A
O	1348	1351	and
B-cv-bin-percent	1352	1353	1
I-cv-bin-percent	1353	1354	.
I-cv-bin-percent	1354	1355	1
I-cv-bin-percent	1355	1356	%
O	1357	1359	in
O	1360	1363	arm
O	1363	1364	-
O	1364	1365	B
O	1365	1366	.

O	1367	1370	The
B-outcome	1371	1372	5
I-outcome	1372	1373	‑
I-outcome	1373	1377	year
I-outcome	1378	1380	in
I-outcome	1380	1381	-
I-outcome	1381	1387	breast
I-outcome	1388	1398	recurrence
O	1399	1400	(
O	1400	1407	outside
O	1408	1410	of
O	1411	1414	the
O	1415	1420	index
O	1421	1429	quadrant
O	1429	1430	)
O	1431	1434	was
B-iv-bin-percent	1435	1436	0
I-iv-bin-percent	1436	1437	%
O	1438	1440	in
O	1441	1444	arm
O	1444	1445	-
O	1445	1446	A
O	1447	1450	and
B-cv-bin-percent	1451	1452	1
I-cv-bin-percent	1452	1453	.
I-cv-bin-percent	1453	1454	2
I-cv-bin-percent	1454	1455	%
O	1456	1458	in
O	1459	1462	arm
O	1462	1463	-
O	1463	1464	B
O	1464	1465	.

O	1466	1473	Salvage
O	1474	1484	mastectomy
O	1485	1488	was
O	1489	1498	performed
O	1499	1511	successfully
O	1512	1514	in
O	1515	1518	all
O	1519	1527	patients
O	1528	1532	with
O	1533	1540	relapse
O	1540	1541	.

O	1542	1546	Long
O	1546	1547	-
O	1547	1551	term
O	1552	1558	follow
O	1558	1559	-
O	1559	1561	up
O	1562	1564	of
O	1565	1569	this
O	1570	1576	single
O	1576	1577	-
O	1577	1583	center
O	1584	1590	cohort
O	1591	1603	consolidates
O	1604	1607	the
O	1608	1615	earlier
O	1616	1623	reports
O	1624	1626	of
O	1627	1630	low
O	1631	1636	local
O	1637	1647	recurrence
O	1648	1653	rates
O	1654	1659	after
O	1660	1666	single
O	1666	1667	-
O	1667	1671	dose
O	1672	1676	IORT
O	1676	1677	.

O	1678	1681	Our
O	1682	1689	results
O	1690	1693	are
O	1694	1696	in
O	1697	1701	line
O	1702	1706	with
O	1707	1710	non
O	1710	1711	-
O	1711	1722	inferiority
O	1723	1725	of
O	1726	1730	risk
O	1730	1731	-
O	1731	1738	adapted
O	1739	1743	IORT
O	1744	1747	for
O	1748	1756	selected
O	1757	1765	patients
O	1766	1770	with
O	1771	1776	early
O	1777	1783	breast
O	1784	1790	cancer
O	1790	1791	.
